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double XY probe, in sex-mismatched pairs, and VNTR, using PCR
with Apo-B, D1S80, vWF and DXS52 primers in all patients.
Mucositis and acute GVHD were more evident in the Bu group.
Late rejection occurred specially in the ATG group. All the others
variables and overall survival were similar between these two con-
ditionings. By FISH evaluation, there were complete chimerism in
8 of 10 patients and there was a case of mixed chimera and another
of autologous reconstitution. VNTR determined chimera in 15 of
17 donor/ recipient pairs (88.2%). Complete chimerism, analyzed
by all primers were seen in 8 of 17 (47%) patients. Mixed chimer-
ism and autologous reconstitution patients, observed by FISH,
were conﬁrmed by VNTR just using D1S80 and vWF primers,
respectively. We conclude that both conditioning regimens were
effective and the analyzed clinical data were comparable between
the groups, however, a larger number of patients need to be studied
in order to establish the best conditioning. The methods for eval-
uation of the chimera are sensitive and informative using VNTR
and FISH methodologies.
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EARLY EXPANSION OF LYMPHOID CELLS PRECEDES MYELOID EN-
GRAFTMENT FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
USING TRULY NONMYELOABLATIVE CYCLOPHOSPHAMIDE/FLUDARA-
BINE CONDITIONING
Pandurangadu, A.V.1, Menggang2, Nelson, R.P.3 1Indiana University
School of Medicine, Indianapolis, IN; 2Department of Medicine, Division
of Biostatistics, Indianapolis, IN; 3Department of Medicine, Division of
Hematology/Oncology and the Indiana University Cancer Center, Indi-
anapolis, IN.
Little is known regarding the mechanism of engraftment of
allogeneic cells in humans, partially because there are few cells to
analyze in the early (ﬁrst 2 weeks) post-transplant period. After
myeloablative conditioning, monocytes are the initial donor cells
identiﬁed in recipients’ blood, followed by polymorphonuclear
leukocytes and then lymphocytes.
Forty-nine consecutive patients with hematological malignancies
(median age, 55 years) received PBMCs from a matched related
(MRD) or unrelated (MUD) donor following cyclophosphamide,
60 mg/kg on days –6 and –7 (total dose 120 mg/kg) and ﬂudara-
bine, 25 mg/m2 for 5 consecutive days (day –5 through day –1; total
dose, 125 mg/m2). GVHD prophylaxis consisted of cyclosporine
(n33) or cyclosporine  mycophenolate mofetil (n16). Acyclo-
vir, ﬂuconazole and quinolone prophylaxis were provided and
freshly harvested, non-manipulated PBMCs were infused within 24
hours of collection. One patient with chronic lymphocytic leuke-
mia (CLL) and a pre-transplant lymphocyte count of 150,000/
mm3 (considered an outlier) was removed from the analysis. A
database (Excel®, MS, Redwood, CA) was utilized to record white
blood counts (WBC) obtained from the computerized medical
record; each patient’s total WBC, neutrophil, lymphocyte, and
monocyte percentages were recorded from day –7 to day 30.
Cumulative data were plotted using S-Plus® software (Insightful,
Seattle, WA) and median times to peak percentages were deter-
mined. Patients who received conventional conditioning and sim-
ilar grafts prior to transplantation for hematological malignancies
(AML or MDS) over a similar time period (n46) were studied and
engraftment patterns compared.
The following phenomena were observed after nonmyeloablative
transplantation: (1) no ¨ bump¨ , (increase in the peripheral WBC)
the day following cell infusion; (2) resolution of neutropenia at a
median of 12 days after MUD transplants and 15 days after MRD
transplants (p0.778); (3) median peak lymphocyte, monocyte and
polymorphonuclear percentages occurred 9, 12 and 23 days post-
infusion, respectively.
Early disappearance of infused cells from the circulation and
relative expansion of lymphocytes preceding the emergence of
monocytes and polymorphonuclear cells suggests that relatively
quick engagement of donor cells by the marrow microenvironment
is followed by an immunologically active process after truly non-
myeloablative cyclophosphamide/ﬂudarabine conditioning.
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NON-MYELOABLATIVE CONDITIONING THERAPY WITH FLUDARABINE,
CYCLOPHOSPHAMIDE AND ATG ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM HLA-IDENTICAL SIBLING DONOR IN
PATIENTS WITH SEVERE APLASIC ANEMIA (SAA)
Pawlowska, A.1, Bolotin, E.1, Falk, P.1, Forman, S.1, LaBossiere, D.1,
Rosenthal, J.1 1City of Hope National Medical and Research Center,
Duarte, CA.
Allogeneic bone marrow transplantation (BMT) from an HLA-
identical sibling is a curative form of therapy for patients with
acquired severe aplastic anemia.
Survival has signiﬁcantly improved over the past 3 decades. The
actuarial risk of rejection has been reduced to about 7%. Improved
results with survival in excess of 90% have been reported. Current
preparative therapies are associated with early and late sequelae
such as acute and chronic graft-versus-host disease (aGvHD or
chGvHD, respectively) and secondary tumors. In two patients (6
years and 11 years old) with SAA, who had an HLA-identical
sibling donor, but could not proceed with myeloablative therapy at
the time of transplant for various reasons (delay in results of
chromosome stability and fragility in one patient and abnormal
pulmonary function in the second), had a non-myeloablative pre-
parative regimen with Fludarabine (30 mg/m2x4 doses) Cyclophos-
phamide (5 mg/kgx4 doses) and rabbit ATG (1.5 mg/kgx4 doses)
followed by an unmanipulated allogeneic BMT. Graft versus host
disease prophylaxis consisted of Cyclosporine from day -1 and
Methotrexate 15 mg/m2 on day1 and 10 mg/m2 on days3,6,
11 after transplant. Myeloid engraftment occurred on day 15
and day 28. The time to a platelet count 20,000 unsupported
was 11 days and 29 days. No transplant-related toxicities,
including mucositis or alopecia, were recorded. There were no
signs for aGvHD or chGvHD. The patients continue with full
donor chimerism 31 months and 6 months post transplant, respec-
tively. This data suggests that a non-myeloablative, immunosup-
pressive regimen is sufﬁcient to provide a stable engraftment in
patients with SAA. This approach may be associated with de-
creased transplant-related short- and long-term toxicities. A larger
study is needed to fully evaluate the outcome and toxicities proﬁle
associated with this conditioning.
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INFLUENCE OF INTERLEUKIN-6 (IL-6) GENE POLYMORPHISM ON THE
OUTCOME OF PATIENTS UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION
Raida, L.1, Faber, E.1, Mrazek, F.2, Indrak, K.1, Petrek, M.2,
Zapletalova, J.3, Ambruzova, Z.2, Kriegova, E.2, Onderkova, J.2 1He-
mato-Oncology Dpt., University Hospital, Olomouc, Czech Republic;
2Dpt. of Biophysics, Medical School of Palacky University, Olomouc,
Czech Republic.
BACKGROUND: IL-6 is an important mediator of inﬂamma-
tion and its production depends on the functional IL-6 gene
polymorphism (IL-6-174*G/C). Allele G expression is associated
with higher IL-6 production. The polymorphism of recipient
and/or donor might inﬂuence immunological reactions after allo-
geneic stem cell transplantation (SCT), particularly graft vs. host
disease (GvHD) and graft vs. tumor (GvT) one.
AIM OF STUDY: To assess the inﬂuence of recipient/donor
functional IL-6 gene polymorphism on the development of acute/
chronic GvHD, tumor relapse and mortality.
PATIENTS AND METHODS: 56 patients were allografted
from HLA-identical related donor. 54 recipients (96%) underwent
the procedure because of incurable hematological malignancy and
33 ones (59%) after reduced intensity conditioning (RIC). IL-6-
174* genotyping of recipients/donors was provided by the use of
polymerase chain reaction with sequential speciﬁc primers (PCR-
SSP). The inﬂuence of GvHD development, tumor relapse and
mortality on the IL-6-174*G/C allele manifestation in recipients/
donors was assessed by the methods of univariate as well as mul-
tivariate statistical analysis.
RESULTS: Statistical analysis did not conﬁrm the signiﬁcant
inﬂuence of functional IL-6 gene polymorphism of recipients/
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donors on GvHD and relapse development or posttransplant mor-
tality.
CONCLUSION: The use of RIC is probably associated with
less expressed inﬂammation (e.g. gastrointestinal tract) and in spite
of allele G presentation (including homozygous form) it might lead
to lower level of IL-6 and lower incidence of severe GvHD. In
contradistinction to previously published analyses of patients al-
lografted after standard myeloablative regimens, the assessment of
this cohort with the frequent use of RICs (59%) failed to prove
IL-6 gene polymorphism to be a universal predictor of posttrans-
plant outcome in such circumstances.
Supported by the Ministry of Education grant MSM
6198959205.
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MAJOR ABO BLOOD GROUP MISMATCH INCREASES THE RISK FOR
GRAFT FAILURE AFTER UNRELATED DONOR HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Remberger, M.1, Watz, E.2, Ringde´n, O.1, Mattsson, J.1, Shanwell, A.2,
Wikman, A.2 1Karolinska Institutet, Clinical Immunology, Karolinska
University Hospital, Stockholm, Sweden; 2Transfusion Medicine, Karo-
linska University Hospital, Stockholm, Sweden.
Two hundred and twenty-four patients with leukemia trans-
planted with an unrelated donor between 1991 and 2003 at Karo-
linska University Hospital were analyzed according to association
between graft failure and ABO, RhD, MNSs and Kidd blood group
antigen compatibility. Median age was 29 years (range 0-55). ).
Two hundred patients and donor pairs were HLA-A, -B, and –DR
identical, and 24 patients had an allele-level mismatched donor
Conditioning consisted of TBI or busulfan-based myeloablative
conditioning. All patients received ATG. A bone marrow graft was
given to 152 patients and 72 patients received peripheral blood
stem cells. Most patients received GVHD prophylaxis with CsA
and MTX.
Results: 135 (60%) patients received an ABO mismatched graft
and 89 received an ABO matched graft. Of the mismatched grafts,
67 (30%) were major mismatched and 68 (30%) minor mis-
matched. A bidirectional mismatch was found in 16 (7%) cases.
Graft failure (GF) was seen in 6 (2.7%) patients. In the multivariate
analysis major ABO mismatch (OR 14.9, 95% CI 2.01-110,
p0.008) and HLA-allele mismatch (6.42, 1.19-34.8, p0.03) was
signiﬁcantly associated to GF. In patients with and without major
ABO mismatch the incidence of GF was 7.5% (5/67) and 0.6%
(1/157)(p0.02), respectively. In patients with and without HLA
allele-level mismatch, the incidence of GF was 8.3% (2/24) and
2.0% (4/200)(p0.09).
Conclusion: Using an ABO major mismatched graft increases
the risk for graft failure after unrelated donor HSCT.
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FLUDARABINE – ORAL BUSULFAN MYELOABLATIVE CONDITIONING
FOR ALLOGENIC PERIPHERAL STEM CELL TRANSPLANTATION. A SIN-
GLE CENTER EXPERIENCE IN COLOMBIA
Rosales, C.1, Abello, V.1, Rosales, E.1, Esguerra, H.1, Linares, A.1
1Clı´nica de Marly, Bogota´, Colombia.
A regimen of busulfan and cyclophosphamide was standard con-
ditioning regimen for allogeneic PBSC in our center for the last 10
years. To reduced toxicity related to high dose cyclophosphamide,
we are using a regimen of ﬂudarabine and oral busulfa´n.
Here we report clinical outcome in the ﬁrst 11 patients treated.
The conditioning regimen consisted of 30 mg/m2 intravenous
ﬂudarabine daily, day -5 to -2, and oral busulfan given at 1 mg/kg
4 times a day every 6 hours from day -5 to -2. Cyclosporine and
methotrexate were used for prophylaxis of GVHD in 9 patients
and Cyclosporine plus mycophenolate in 2.
Diagnoses were: AML in 5; MDS, NHL, ALL, NPH 1 each, and
CML in 2. The median patient age was 40 years (range, 17-59
years). Mobilized blood stem cells were obtained from HLA-
compatible siblings. Engraftment was achieved in all but one pa-
tient, who had high risk MDS, received a second transplant after
loosing the ﬁrst graft a year before, and died on day 34. At a
median follow up of 3.5 months (range 5.3-1.25) all other patients
are alive (day 100 transplant related mortality 7%). The median
time for neutrophil and platelet recovery were 10.9 (min 7, max
13) and 12 (min 0, max 15) days. There was no cardiac toxicity
and hemorrhagic cystitis. Grade 1-2 and grade 3 mucositis oc-
curred in 45% and 27% respectively. Of 10 evaluable patients 7
had acute GVHD grade 1-2 and 1 grade 3. 70% of patients became
CMV and received pre-emptive therapy.
Fludarabine – oral busulfan has been well tolerated in standard
conditioning regimen versus cyclophosphamide – oral busulfan,
but longer follow up is needed to establish deﬁnitive conclu-
sions.
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REDUCED RISK OF RELAPSE IN PEDIATRIC PATIENTS AFTER DOUBLE
UNIT CORD BLOOD TRANSPLANTATION? A SINGLE INSTITUTION EX-
PERIENCE
Rosenthal, J.1, Bolotin, E.1, Pawlowska, A.1, Falk, P.1, Hitt, D.1,
Forman, S.1 1City of Hope National Medical and Research Center,
Duarte, CA.
Unrelated umbilical cord blood transplantation (UCBT) has be-
come a standard therapeutic option for pediatric patients who may
beneﬁt from hematopoietic stem cell transplantation but lack an
adequate HLA-identical related donor. UCBT has the advantages of
rapid availability and presumably lower risk of severe, acute GVHD
despite donor-recipient HLA disparity. Double-unit UCBT
(DUCBT) extends access to transplantation for patients who were
previously disqualiﬁed on the basis of low cell dose in a single unit.
Recent studies report high engraftment rate, acceptable rates of severe
acute GVHD and acceptable rates of transplantation-related mortal-
ity with DUCBT. (Barker Blood. 2005;105:1343-1347). It is un-
known, however, whether patients with advanced hematological ma-
lignancies and patients with severe co-morbidities would beneﬁt from
DUCBT. DUCBT was given to 7 patients with advanced hemato-
logical malignancies (AML,n3, refractory n1, 2CR n1, 3CR
n1, ALL, n4; 1CR Ph n 1, 2CR Ph n1, both MRD,
2CR n2). The males/female ratio was 5/2. Ages were 5.2-15 yrs
(median 14 yr). Five of seven were non-Caucasian (71%). Co-mor-
bidities included invasive fungal infection (n3), acute pancreatitis
(n1), and bulbar paralysis (n1). Conditioning regimes were FTBI
and melphalan (n3) and ﬂudarabine with melphalan (n4). Myeloid
engraftment occurred in all patients. The median time to an absolute
neutrophil count500 was 34 days (range 26-74 days). Three patients
remained platelet transfusion dependent after day 100. In the remain-
ing 4 patients the median time to a platelet count 20,000 unsup-
ported were 51 days (range 44-69 days). All patients (100%) experi-
encedGrades II-III acuteGVHD.There were no patients withGrade
IV GVHD and no deaths from acute GVHD. Four patients devel-
oped extensive chronic GVHD of the skin only. The 100 day trans-
plant related mortality was 0%. One patient died on day  200 from
respiratory failure secondary to multiple recurrent viral infections
(CMV, Parainﬂuenza type 3, and herpes simplex virus). None of the
patient suffered relapse. The disease-free survival is 80% with a
median day 405 post transplant (range 173-1126). The observation
that DUCBT may be associated with a reduced risk of relapse in
patients with high-risk leukemia deserves further evaluation. Larger
studies will be needed to conﬁrm the clinical observation and inves-
tigate what are the potential mechanisms by which DUCBT could
mediate an anti-leukemic effect.
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UMBILICAL CORD BLOOD TRANSPLANTATION USING NON-MYELOAB-
LATIVE CONDITIONING: THE MEXICAN EXPERIENCE
Mancias-Guerra, C.1, Ruiz-Delgado, G.J.1, Manzano, C.2,
Diaz-Hernandez, M.A.2, Tarin-Arzaga, L.C.1, Gonzalez-Llano, O.1,
Calderon, E.D.3, Gomez-Almaguer, D.1, Ruiz-Arguelles, G.J.2 1Hos-
pital Universitario de Nuevo Leon, Monterrey, NL, Mexico; 2Centro de
Hematologia y Medicina Interna de Puebla, Puebla, PUE, Mexico;
3CordMX. Centro Nacional de la Transfusion Sanguı´nea, Mexico City,
DF, Mexico.
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